ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS

Ph-negative myeloproliferative neoplasm are the group of hematologic disorders which includes primary myelofibrosis, polycythemia vera, essential trombocytemia and several rare diseases. After the discovery of V617 Fgain-of-function mutation the new period of diagnostics, treatment and evaluating of MPN prognosis began. At the current moment several molecules inhibiting JAK2 function are developed. Advanced therapy in patients with primary and post-polycythemic myelofibrosis included molecules inhibiting JAK2 function resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the phase 3 trials COMFORT-I and COMFORT-II. The effectiveness of the advanced therapy included molecule inhibiting JAK2 was evaluated in three patients with primary myelofibrosis and post-polycitemic myelofibrosis. All represented clinical cases demonstrated positive dynamics of the disease manifested in spleen size reduction, improvement of the symptoms and in one case in reduction of blood transfusions. None of three patients met serious adverse events leading to dose reduction or discontinuation of the molecule inhibiting JAK2. Target agents therapy demonstrated high treatment rates in patients with primary and post-polycythemic myelofibrosis. Thus, it is clearly necessary to perform molecular diagnosis, screening tests at early stages of the chronic myeloproliferative disease for the selection of patients in need for specific treatment

CORTEXIN IN THE PREVENTION OF SYNDROME OF INTRACRANIAL HYPERTENSION AT THE EFFECTS OF CLOSED CRANIOCEREBRAL INJURY

The syndrome of intracranial hypertension at the effects of closed craniocerebral injury manifests functional and. organic disorders of varying degrees of severity. In our work we used the method of assessing of the degree of intracranial hypertension. (ICH) by measurement of distances between the structures of the brain using magnetic resonance imaging. Calculation of index of restriction of the posterior cranial fossa allowed to compare the data of 47 patients with ICH. Studies have shown that the exchange rate of application of the drug Cortexin is an effective means of preventing intracranial hypertension in the remote period intracranial injury and. can be recommended for wide use of this product both in the hospital and. in the outpatient clinic-conditions

THE FUNCTIONAL STATE OF VISUAL ANALYZER IN PATIENTS WITH CHRONIC VERTEBROBASILAR INSUFFICIENCY

All patients had various stages of fundus changes typical for the arterial hypertension, a significant reduction in the flicker fusion frequency. When an overall insignificant decrease in ERG amplitude and prolongation of the latency time was determined of a- and. b-waves compared with the control group, decreased the amplitude of oscillatory potentials. Indices of the lability and. sensitivity of the optic nerve were within normal limits. The use new electrophysiological diagnostic methods could be perspective for identification and. assessment of the degree of pathological changes in the visual analyzer at an early sub-clinical level of disease in violation of circulation in the vertebral-basilar basin